Antiemetic Therapy
Introduction to Antiemetic Medications
- Antiemetic medications such as metoclopramide, prochlorperazine, and ondansetron are used to prevent and treat nausea and vomiting, with the American College of Physicians and other guideline societies recommending their use as individual agents for antiemetic therapy 1, 2
- The National Comprehensive Cancer Network suggests using these agents individually rather than in combination, due to the increased risk of severe extrapyramidal symptoms 3
First-Line Antiemetic Options
- Metoclopramide 10-20 mg PO/IV every 6 hours is a recommended first-line option for antiemetic therapy, according to the National Comprehensive Cancer Network 3
- Prochlorperazine 5-10 mg PO/IV every 6-8 hours is also a recommended first-line option 3, 4
- Ondansetron 8 mg PO/IV every 8-12 hours is another first-line option, according to the American Gastroenterological Association 1, 5
Refractory Nausea Management
- For refractory nausea, the World Journal of Emergency Surgery suggests adding a second agent with a different mechanism of action, such as ondansetron if using metoclopramide 4, 5
- The National Comprehensive Cancer Network recommends considering dexamethasone as an adjunct for refractory nausea 4
- Opioid rotation should be considered if nausea is opioid-induced, according to the National Comprehensive Cancer Network 5
Medication Selection and Dosing
- Metoclopramide is preferred over prochlorperazine, according to the American Gastroenterological Association 1
- Ondansetron should be used as a second-line therapy after metoclopramide, as recommended by the American Gastroenterological Association 1
- The typical administration frequency of metoclopramide is every 6 hours (4 times daily) or every 8 hours (3 times daily), with a standard dose of 5-20 mg orally or intravenously 3, 6
- The maximum daily dose is 0.5 mg/kg/day, typically not exceeding 40 mg daily, with a recommended starting dose of approximately half the recommended dose for patients with creatinine clearance below 40 mL/min 6
Special Considerations
- Elderly patients should start at lower doses (5-10 mg) and be monitored closely, as they may be more susceptible to adverse effects, with a recommended dose reduction of approximately 50% if creatinine clearance is below 40 mL/min 3
- Metoclopramide should be avoided in patients with a history of tardive dyskinesia, Parkinson's disease, or seizure disorders, with high-risk groups including elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic therapy 3, 7, 8
- Exercise particular caution with either medication (and absolutely avoid the combination) in elderly patients, patients with cerebral palsy or other neurological disorders, patients with renal or hepatic impairment, and patients already taking other antipsychotic medications, as recommended by the American College of Physicians 3, 4, 1, 5
Monitoring and Adverse Effects
- Patients should be assessed for symptom improvement within 24-48 hours of initiating combination therapy, with monitoring for adverse effects, particularly extrapyramidal symptoms (acute dystonia, akathisia), sedation, and QT prolongation (when combined with ondansetron) 3
- The risk of tardive dyskinesia increases with longer duration of treatment, and is approximately 0.1% per 1000 patient years, as reported by the National Comprehensive Cancer Network 7, 8
- Ondansetron can prolong the QT interval, which may be exacerbated when combined with other medications 2
Alternative Indications and Administration Routes
- Metoclopramide can be used for various indications, including radiation therapy-induced nausea (5-20 mg as breakthrough therapy), pregnancy-related nausea (10 mg three times daily), migraine-associated nausea (10 mg orally or IV as adjunctive therapy), GERD/reflux (10 mg three to four times daily), and lower GI bleeding preparation (10 mg IV approximately 30 minutes before bowel purge) 6, 1, 9, 10, 11, 12
- The preferred route of administration for ongoing therapy is oral, while parenteral use (IV/IM) should be limited to 1-2 days when possible, as guided by the National Comprehensive Cancer Network 7, 8